UCB and Synosia Therapeutics sign strategic alliance in neurology
Synosia grants UCB exclusive worldwide rights to an adenosine A2a antagonist (SYN-115) and rights to a second compound (SYN-118), both for patients living with movement disorders such as Parkinson’s disease
12-Oct-2010 -
UCB and Synosia Therapeutics announced a new strategic partnership in neurology. Synosia has granted UCB a license for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications. Both are in Phase II clinical development ...
adenosine
inhibitors
milestone payments
+3